mAbs (Monoclonal Antibodies)

Biosol is establishing a comprehensive monoclonal antibody platform designed to support programs from development through commercial manufacturing. By combining advanced development technologies, GMP manufacturing infrastructure and scalable production capabilities, Biosol aims to provide a seamless pathway from process development and analytical characterization to clinical and commercial supply.

Capabilities Include

• Analytical Development
• Formulation Development
• Purification
• GMP Manufacturing

Manufacturing Scale

• 5L - 200L Development Bioreactors
• 1000L GMP Pilot Manufacturing
• 5000L Commercial Manufacturing
• Cell Line & Process Development

CHO cell line development, upstream process development and downstream process development supporting scalable manufacturing.